Ref D3
Computational Service
Confidence Reported
Scoped After Feasibility Review
Service Overview
Metabolism decides how long a compound survives and whether it can be dosed alongside other drugs. We predict microsomal and hepatocyte stability, identify the sites of metabolism that drive clearance, assess inhibition across the major cytochrome P450 isoforms, and flag structures likely to generate reactive metabolites. The practically useful part is the soft-spot map: it tells the chemistry team exactly which position to block, fluorinate or replace.
Key Features & Advantages
Soft Spots Mapped To Atoms
Sites of metabolism are predicted at atom level and ranked by likelihood, converting a stability problem into a specific, actionable structural modification.
Isoform-Resolved CYP Assessment
Inhibition is predicted per isoform across 1A2, 2C9, 2C19, 2D6 and 3A4, since drug–drug interaction risk depends on which enzyme is involved and on the co-medication landscape.
Reactive Metabolite Alerts
Structural alerts and predicted bioactivation pathways are reported with the mechanism, which matters for idiosyncratic toxicity risk and for regulatory discussion.
Metabolite Structures Proposed
Likely metabolite structures are generated, helping analytical teams design the identification study rather than search blind.
Where This Service Is Used
1Diagnosing rapid clearance observed in microsomal or hepatocyte assays
2Guiding structural blocking of a metabolic soft spot in a lead series
3Assessing drug–drug interaction risk ahead of candidate selection
4Screening for reactive metabolite liabilities in a series carrying structural alerts
5Supporting metabolite identification studies by predicting what to look for
Methods and Techniques Applied
1Site-of-metabolism prediction for major P450 isoforms with atom-level ranking
2Intrinsic clearance and half-life prediction for microsomal and hepatocyte systems
3CYP inhibition prediction per isoform, with reversible and time-dependent inhibition distinguished where models permit
4Metabolite structure generation for the most probable transformation pathways
5Structural alert screening for bioactivation and reactive intermediate formation
6Series-level interpretation relating predicted stability to the structural changes across the SAR
What We Need From You
1Compounds as SMILES or SDF with stereochemistry defined
2Any measured stability, clearance or CYP inhibition data available for calibration
3Species of interest, since human, rat, mouse and dog metabolism differ substantially
4Known metabolites or metabolite identification data if a study has already been run
What You Receive
1Predicted stability and clearance values per compound with confidence indicators
2Soft-spot maps highlighting predicted sites of metabolism on each structure
3CYP inhibition profile by isoform with interaction risk commentary
4Proposed metabolite structures for the dominant predicted pathways
5Structural modification recommendations targeted at the specific liabilities identified
What We Compute and Report
1Predicted intrinsic clearance and half-life for microsomal and hepatocyte systems, by species
2Atom-level site-of-metabolism ranking showing exactly which positions are vulnerable
3Inhibition likelihood for each major cytochrome P450 isoform
4Proposed metabolite structures for the dominant predicted transformation pathways
5Bioactivation and reactive metabolite alerts with the mechanism identified
Questions We Are Asked Before Scoping
How accurate is clearance prediction?
▸Rank ordering within a chemical series is usually informative; absolute clearance values are not reliable enough to replace measurement. The soft-spot map is generally the more actionable output.
Can you predict human clearance from structure alone?
▸Only approximately. Human clearance depends on multiple enzyme systems, transporters and protein binding. Prediction guides design; in vitro measurement and scaling remain required.
Will blocking the predicted soft spot solve the problem?
▸Often it shifts metabolism to the next most labile site rather than removing it. We report the ranked list of sites so the likely consequence of blocking each one is visible in advance.
Interpretation and Limitations
Computational predictions prioritise hypotheses; they do not independently establish binding, biological activity, therapeutic efficacy, safety or clinical validity. Performance depends on input quality, target class, the structural evidence available and the applicability domain of the selected methods. Scores used for ranking are comparative devices and should not be read as measured quantities. All deliverables are for research use only and are not intended for diagnostic or therapeutic use.
Is This the Right Service for You?
Choose this when
Microsomal or hepatocyte clearance is too high and the cause is unclear
Drug–drug interaction risk needs assessing ahead of candidate selection
An analytical team needs structural hypotheses for unidentified metabolite peaks
Consider another service when
Exposure is limited by absorption rather than by metabolism
Absorption & Permeability Prediction The concern is reactive metabolite toxicity rather than clearance
Toxicity & Safety Profiling What Goes Wrong, and How We Handle It
These are the failure modes that produce confident-looking results which do not survive the next experiment. Each one is designed against rather than discovered afterwards.
Blocking the predicted soft spot only to shift metabolism elsewhere
The full ranked list of labile positions is delivered, so the likely consequence of blocking each one is visible in advance.
Human clearance inferred from rodent data or from structure alone
Species-specific models are applied and the limits of cross-species extrapolation are stated.
CYP inhibition treated as a single property
Inhibition is predicted per isoform, since interaction risk depends on which enzyme and on the co-medication landscape.
A Worked Example
Locating the metabolic soft spot in a lead series
The situation
Half-life in human microsomes was under five minutes across every analogue tested.
What the work involved
Atom-level sites of metabolism were predicted for each compound, metabolite structures were proposed for the dominant pathways, and predicted stability was compared against the measured values for calibration.
What came back
A benzylic position was the primary site in every analogue. Fluorination and ring-contraction options were proposed, with the next most labile position identified so the team knew what would surface afterwards.
Illustrative of the shape this work takes. Details are generalised, no client or target is identified, and scope and outcome vary with the system in question.
What Published Work Reports
The results below were published by independent groups and are cited to show what these computational approaches have achieved in the literature. They are not ICDMO project results, and outcomes vary substantially between targets, datasets and programmes. We do not promise comparable results for any particular project.
Property prediction is accurate enough to triage, not to replace measurement
Across the published literature, lipophilicity and surface-property predictions are generally reliable, while aqueous solubility models typically carry errors around one log unit and absolute human pharmacokinetic prediction remains weak. We therefore report predictions with their expected error and applicability-domain status, and recommend measurement at the point where a decision turns on the number rather than the rank order.
Method comparison literature, ongoing ↗Service Workflow
1
Scientific Consultation
We discuss the objective, the decision it supports and the data you hold. Nothing is quoted before we understand what the result has to answer.
2
Feasibility Review
We check that the data, target class and available structural evidence can support the proposed approach, and say plainly where they cannot.
3
Technical Proposal
Scope, methods, deliverables, timeline and price are confirmed in writing, together with the limitations we expect to report.
4
Computation and QC
The analysis runs on pinned tool versions in a containerised environment, with quality checkpoints and method comparison where that is informative.
5
Report and Follow-Up
You receive the ranked results, the documented methods, the limitations and a proposed validation plan, plus support in interpreting them.
Service Process
1
Online Consultation
›
2
Solution Matching
›
3
Service Contract
›
4
Project Execution
›
5
Data Delivery
Specifications & Turnaround
Note: ICDMO delivers computational (in silico) services. Results prioritise hypotheses for testing; they do not by themselves establish binding, biological activity, efficacy or safety. All deliverables are for research use only and are not intended for diagnostic or therapeutic use. Downstream experimental work is scoped separately and executed through qualified partners.
Get a Custom Quote
Our scientific team responds within 24 hours with a detailed technical proposal and pricing tailored to your project.
Contact Us Online ConsultationStandard Deliverables
✓Sequence-verified final product
✓Full QC documentation
✓Certificate of Analysis (CoA)
✓Electronic data files
✓Project completion report
Why ICDMO?
Computational CDMO Focus
Reproducible, Versioned Pipelines
Confidence & Limitations Reported
Experiment-Aware Recommendations
Response Within One Business Day